186 related articles for article (PubMed ID: 27150142)
1. Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model.
Kimura K; Kanehira N; Takayanagi R; Minohara H; Homma M; Yamada Y
Biol Pharm Bull; 2016; 39(5):705-11. PubMed ID: 27150142
[TBL] [Abstract][Full Text] [Related]
2. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
[TBL] [Abstract][Full Text] [Related]
4. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Herrington JD; Dinh BC
J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
[TBL] [Abstract][Full Text] [Related]
5. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Oldfield V; Perry CM
Drugs; 2006; 66(4):529-45. PubMed ID: 16597166
[TBL] [Abstract][Full Text] [Related]
6. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Patel KS; Lau JE; Zembillas AS; Gallagher EM
J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
[TBL] [Abstract][Full Text] [Related]
7. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
[TBL] [Abstract][Full Text] [Related]
9. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy.
Liu CY; Sims-McCallum RP; Schiffer CA
Leuk Res; 2005 Apr; 29(4):463-5. PubMed ID: 15725482
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
[TBL] [Abstract][Full Text] [Related]
11. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
12. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Campara M; Shord SS; Haaf CM
J Clin Pharm Ther; 2009 Apr; 34(2):207-13. PubMed ID: 19250141
[TBL] [Abstract][Full Text] [Related]
13. Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Hooman N; Otukesh H
Iran J Kidney Dis; 2011 Mar; 5(2):130-2. PubMed ID: 21368393
[TBL] [Abstract][Full Text] [Related]
14. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy.
Hutcherson DA; Gammon DC; Bhatt MS; Faneuf M
Pharmacotherapy; 2006 Feb; 26(2):242-7. PubMed ID: 16466328
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease.
Sestigiani E; Mandreoli M; Guardigli M; Roda A; Ramazzotti E; Boni P; Santoro A
Nephron Clin Pract; 2008; 108(4):c265-71. PubMed ID: 18418005
[TBL] [Abstract][Full Text] [Related]
16. Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients.
Depreter B; Stove V; Delanghe J
Clin Biochem; 2016 Dec; 49(18):1390-1395. PubMed ID: 27129796
[TBL] [Abstract][Full Text] [Related]
17. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
[TBL] [Abstract][Full Text] [Related]
18. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Kennedy LD; Ajiboye VO
J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
[TBL] [Abstract][Full Text] [Related]
19. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
